| 04.06.18 | Incyte hit hard as Merck combo flops, with questions rising over IDOs; Unity in $85M IPO play

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

6 jahre vor

Html
Text

To view this email as a web page, click here

This week's sponsor is Premier Research.
	Opportunity Knocks: Seizing the Promise of Orphan Drugs Orphan drug developers enjoy more favorable regulatory conditions today than ever. Read our white paper for tips on maximizing this opportunity. Premier Research. It's what we do. Best.

Today's Rundown

Body blow for Incyte as Merck-partnered melanoma trial bombs Unity files for $85M IPO to take anti-aging drugs into phase 1 Novo moves into sickle cell with $400M EpiDestiny deal [Sponsored] Personalized Medicine Requires Personalized Measurement Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment EuroBiotech Report—Sofinnova’s fund, ITB bags $67M, Nanovector delay, AstraZeneca’s I-O deal and more FiercePharmaAsia—U.S.-China trade battle, Takeda-Shire deal insight, China’s generics push Chutes & Ladders—Celgene COO abruptly resigns amid immunology setbacks

Featured Story

Body blow for Incyte as Merck-partnered melanoma trial bombs

Friday, April 6, 2018

The combination of Incyte’s epacadostat and Merck & Co.’s Keytruda was supposed to pose a major threat to rival Bristol-Myers Squibb’s melanoma franchise—but the data tell a different story.

This week's sponsor is STEMCELL Technologies.

Unity files for $85M IPO to take anti-aging drugs into phase 1

Friday, April 6, 2018

Unity Biotechnology has filed for an $85 million IPO. Hitting the target would bring the preclinical anti-aging startup’s fundraising haul up toward $300 million and set it up to move two assets into the clinic.

Novo moves into sickle cell with $400M EpiDestiny deal

Friday, April 6, 2018

Novo Nordisk has moved into sickle cell disease through a licensing deal with EpiDestiny. The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.

[Sponsored] Personalized Medicine Requires Personalized Measurement

Monday, April 2, 2018

How we measure outcomes will evolve from applying one solution to finding an empirical basis for a highly customized application of all of them. Personalized medicine needs a more personalized approach to measurement. Read more.

Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment

Friday, April 6, 2018

Injectable drugs used to treat inflammatory arthritis are usually cleared quickly from joints, limiting their effectiveness. A PureTech startup is developing an immune-responsive hydrogel system that releases a corticosteroid into arthritic joints based on their level of inflammation.

EuroBiotech Report—Sofinnova’s fund, ITB bags $67M, Nanovector delay, AstraZeneca’s I-O deal and more

Thursday, April 5, 2018

In this week's EuroBiotech Report, Sofinnova Partners raised €275 million on later-stage bets, while ITBMed raised $67 million. Meantime, Nordic Nanovector delayed a pivotal lymphoma trial readout.

FiercePharmaAsia—U.S.-China trade battle, Takeda-Shire deal insight, China’s generics push

Friday, April 6, 2018

A long list of biopharma products from China are proposed targets for additional U.S. tariffs, analysts now think the Takeda-Shire deal is "more likely than not," China puts forward a policy package that favors generics over brands and more.

Chutes & Ladders—Celgene COO abruptly resigns amid immunology setbacks

Friday, April 6, 2018

Celgene COO Scott Smith steps down after recent setbacks, former Kite leaders Belldegrun and Chang are back at a new CAR-T shop, former GSK Dermatology executive Rubenstein is among several C-suite hires at Dermavant, plus more hirings, firings and retirings throughout the industry.

This week's sponsor is Sensors Expo.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Resources

[Whitepaper] 2018 Life Sciences Trends

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

[Whitepaper] The Future of Life Sciences Events Management

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Presented by: Patheon, part of Thermo Fisher Scientific

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

Presented by: Charles River

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Presented by: Covance

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.